Abstract

Both EZH2 and its homolog EZH1 function as histone H3 Lysine 27 (H3K27) methyltransferases and repress the transcription of target genes. Dysregulation of H3K27 trimethylation (H3K27me3) plays an important role in the development and progression of cancers such as hepatocellular carcinoma (HCC). This study investigated the relationship between the expression of EZH1/2 and the level of H3K27me3 in HCC. Additionally, the role of EZH1/2 in cell growth, tumorigenicity, and resistance to sorafenib were also analyzed. Both the lentiviral knockdown and the pharmacological inhibition of EZH1/2 (UNC1999) diminished the level of H3K27me3 and suppressed cell growth in liver cancer cells, compared with EZH1 or EZH2 single knockdown. Although a significant association was observed between EZH2 expression and H3K27me3 levels in HCC samples, overexpression of EZH1 appeared to contribute to enhanced H3K27me3 levels in some EZH2lowH3K27me3high cases. Akt suppression following sorafenib treatment resulted in an increase of the H3K27me3 levels through a decrease in EZH2 phosphorylation at serine 21. The combined use of sorafenib and UNC1999 exhibited synergistic antitumor effects in vitro and in vivo. Combination treatment canceled the sorafenib-induced enhancement in H3K27me3 levels, indicating that activation of EZH2 function is one of the mechanisms of sorafenib-resistance in HCC. In conclusion, sorafenib plus EZH1/2 inhibitors may comprise a novel therapeutic approach in HCC.

Highlights

  • Both EZH2 and its homolog enzymatic inhibition differs between GSK126 (EZH1) function as histone H3 Lysine 27 (H3K27) methyltransferases and repress the transcription of target genes

  • It is possible that EZH1 rather than EZH2 was associated with the high levels of H3K27me[3] in some E­ ZH2lowH3K27me3high samples

  • EZH1/2 double knockdown demonstrated an additional inhibitory effect on cell growth and sphere formation in hepatocellular carcinoma (HCC) cells compared to single knockdown

Read more

Summary

Introduction

Both EZH2 and its homolog EZH1 function as histone H3 Lysine 27 (H3K27) methyltransferases and repress the transcription of target genes. Dysregulation of H3K27 trimethylation (H3K27me3) plays an important role in the development and progression of cancers such as hepatocellular carcinoma (HCC). Combination treatment canceled the sorafenibinduced enhancement in H3K27me[3] levels, indicating that activation of EZH2 function is one of the mechanisms of sorafenib-resistance in HCC. Epigenetics refers to regulatory gene expression mechanisms, which do not involve changes in the DNA sequence This includes DNA methylation, histone modification, non-coding RNAs, and chromatin ­remodeling[7,8]. Epigenetic machinery dysregulation plays a critical role in the development and progression of various cancers, including ­HCC9,10

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.